论文部分内容阅读
目的观察比较雷贝拉唑与奥美拉唑治疗幽门螺杆菌相关性消化性溃疡的临床有效性与安全性。方法选取医院收治的30例消化性溃疡患者作为研究对象,14C呼气检测均为阳性,随机分为观察组和对照组,每组15例。观察组给予口服雷贝拉唑治疗,对照组给予口服奥美拉唑治疗。2组同时给予阿莫西林和克拉霉素口服治疗。观察并记录2组腹痛、腹胀、嗳气症状改善时间、患者用药不良反应及临床疗效;内镜检查观察患者溃疡愈合情况;14C呼吸检测观察Hp清除率。结果观察组腹痛、腹胀、嗳气缓解时间均短于对照组(P均<0.05);2组有效率均为100%;用药期间,2组患者均未见明显不良用药反应;观察组治疗后Hp清除率(100%)与对照组(93.3%)比较差异无统计学意义(P>0.05)。结论雷贝拉唑或奥美拉唑治疗幽门螺杆菌相关性消化性溃疡均具备良好临床疗效,可有效改善患者临床症状,促进溃疡面愈合,且用药安全可靠,但雷贝拉唑代谢过程不受CYP450酶系统影响,效果较为稳定,更具临床应用价值。
Objective To compare the clinical efficacy and safety of rabeprazole and omeprazole in the treatment of Helicobacter pylori-associated peptic ulcer. Methods Thirty patients with peptic ulcer admitted to our hospital were selected as the study subjects. 14C breath test was positive and randomly divided into observation group and control group, 15 cases in each group. The observation group was given oral rabeprazole, while the control group was given oral omeprazole. Two groups were given oral treatment with amoxicillin and clarithromycin. Observe and record two groups of abdominal pain, abdominal distension, the symptoms of asthma to improve time, adverse drug reactions and clinical efficacy of patients; endoscopic examination of patients with ulcer healing; Hp clearance rate observed by 14C respiration. Results The abdominal pain, abdominal distension and belching time in the observation group were shorter than those in the control group (all P <0.05), and the effective rates in both groups were 100%. No significant adverse reactions were observed in the two groups during the treatment period. Hp There was no significant difference in clearance rate (100%) and control group (93.3%) (P> 0.05). Conclusion Rabeprazole or omeprazole have good clinical efficacy in the treatment of H.pylori associated peptic ulcer, which can effectively improve the clinical symptoms of patients and promote the healing of ulcers, and the medication is safe and reliable, but the metabolic process of rabeprazole is not By CYP450 enzyme system, the effect is more stable, more clinical value.